Back to dashboard
CommercialCoverageMedium impact

11.14.06j, Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)

Independence Blue Cross·Orthopedics, Sports Medicine·Medical Policy
Effective date
Apr 16, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

Independence Administrators has reissued their medical policy for Autologous Chondrocyte Implantation (ACI) and other cell-based treatments for focal articular cartilage lesions. This is a policy reissue rather than substantive changes, but billing teams should review for any updated coverage criteria or documentation requirements.

Action Required

Action needed
By April 16, 2025: Billing team must review the updated policy 11.14.06j for any changes to coverage criteria, prior authorization requirements, or documentation standards for autologous chondrocyte implantation and cell-based cartilage treatments. Update internal billing guidelines and notify providers of any changes affecting these specialized orthopedic procedures.

Related policy hubs